FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer

Frontiers in Immunology

Randy F. Sweis²  Alec Kacew³ 

[1] Committee on Immunology, The University of Chicago, Chicago, IL, United States;Comprehensive Cancer Center, The University of Chicago, Chicago, IL, United States;Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States;

关键词: bladder cancer;    fibroblast growth factor receptor;    immunotherapy;    pharmacogenetics;    targeted molecular therapy;   

DOI  :  10.3389/fimmu.2020.575258

来源: DOAJ

【 摘 要 】

FGFR3 is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as a marker and target in the context of immunotherapy is incompletely understood. We review the role of FGFR3 in bladder cancer and discuss preclinical and clinical clues of its effectiveness as a patient selection factor and therapeutic target in the era of immunotherapy.

【 授权许可】

Unknown